Exploration (Beijing, China)Sep 9, 2026

Designing mRNA Nanoparticle Medicines for the Ageing Brain: Potential and Challenges in Treating Neurodegenerative Diseases

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Sep 10, 2026

Abstract

mRNA therapeutics delivered by lipid nanoparticles (LNPs) have the potential to address neurodegenerative diseases but have not yet been tested in clinical trials.

Recent advances in engineering LNPs may enable them to cross the blood-brain barrier and selectively express in ageing brain cells.
Emerging chemistries, such as BBB-shuttling lipids and peptide-functionalized shells, could facilitate systemic delivery to the central nervous system in animal models.
First-in-human studies for rare metabolic disorders indicate favourable safety profiles and manufacturability for mRNA-LNPs.
Challenges remain in achieving efficient delivery and expression durability in aged neurons and addressing chronic-dose immunogenicity.
Proposed design rules and analytical standards aim to close knowledge gaps related to age-related changes in the blood-brain barrier.

Simplified

Messenger RNA (mRNA) therapeutics delivered by lipid nanoparticles (LNPs) have advanced from concept to clinic at unprecedented speed, yet their promise for neurodegenerative diseases remains largely untapped. Currently intractable age-related proteinopathies such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis demand new therapies that combine molecular precision with scalable manufacturing. This review surveys recent advances in engineering LNPs that traverse the blood-brain barrier (BBB), evade innate immune surveillance, and achieve cell-selective expression in the ageing brain. We highlight emerging chemistries, including BBB-shuttling ionizable lipids, peptide-functionalized shells, and liver-detargeted formulations that enable systemic or minimally invasive delivery to the central nervous system (CNS) in animal models. Although no CNS-directed mRNA-LNP has yet reached clinical trials, first-in-human studies for rare metabolic disorders demonstrate favourable safety, manufacturability, and durable protein replacement. Drawing lessons from COVID-19 mRNA vaccines and ongoing liver-targeted programmes, we outline a translational roadmap for brain applications. Major hurdles that are critically assessed include efficient endosomal escape in aged neurons, heterogeneity of the senescent BBB, chronic-dose immunogenicity, and large-scale synthesis of next-generation lipids. Finally, we propose design rules and analytical standards to address outstanding knowledge gaps in expression durability and age-related BBB alterations. Together, these insights chart a path for engineering mRNA-LNP therapeutics capable of meeting the rising burden of neurodegenerative diseases in an ageing global population.